PROCEPT BioRobotics sets November 4 results date: what it means for PROCEPT BioRobotics stock

Published on 10/16/2026 at 00:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 94.50 million in the second quarter, up 19.30 percent year over year. A USD 20.00 target frames PROCEPT BioRobotics stock.

Results date and operating scale

Third-quarter results are scheduled for November 4, 2026.
Second-quarter revenue reached USD 94.50 million, up 19.30 percent year over year.
Leerink Partners set a USD 20.00 target on October 12, 2026.

PRCT, US74276L1052, Illustration mit AI erstellt.

PROCEPT BioRobotics (ISIN US74276L1052) scheduled its third-quarter 2026 results for November 4, 2026, giving investors a firm date for the next operating update. According to PROCEPT BioRobotics, management will discuss the figures during a conference call at 4:30 p.m. ET on the same date. The result will test whether the company can extend the growth shown in its second-quarter report.

Three events shape the setup

The chronology points to a business still expanding while losses remain material. On August 4, 2026, PROCEPT reported second-quarter revenue of USD 94.50 million and a GAAP net loss of USD 26.86 million, according to Markets Insider. On October 12, 2026, Leerink Partners maintained a Hold rating and set a USD 20.00 price target, the same report said. Also on October 12, PROCEPT announced that it would publish third-quarter results on November 4, 2026, after the market close.

What does November 4 mean for growth?

The second-quarter revenue figure was 19.30 percent above the USD 79.18 million reported for the same period a year earlier. MarketBeat also reported that the company missed quarterly earnings expectations, posting adjusted earnings per share of minus USD 0.47 versus a consensus estimate of minus USD 0.46. The combination puts execution and profitability at the center of the November update.

Next date and analyst reference

The next substantiated company date is November 4, 2026, when PROCEPT is scheduled to report third-quarter results after the market close. The conference call is set for 4:30 p.m. ET, giving investors a second time marker for management commentary. Leerink's USD 20.00 target provides a dated analyst reference, while the company enters the report with a recent revenue comparison and a continuing GAAP net loss.

Business scale remains the anchor

PROCEPT BioRobotics develops robotic and image-guided systems for urologic procedures, with Aquablation therapy as its central commercial application. Its market capitalization was USD 1.0 billion as of October 15, 2026, and its 52-week range was USD 16.67 to USD 38.11.